logo-loader
RNS
viewFutura Medical PLC

Futura Medical PLC - Notice of Results

RNS Number : 1732G
Futura Medical PLC
16 March 2020
 

 

16  March 2020

 

Notice of Results 2019

 

Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal technology DermaSys® and currently focused on sexual health and pain, will announce its audited results for the year ended 31 December 2019 on Wednesday, 1 April 2020.

 

James Barder, Chief Executive Officer, Angela Hildreth, Finance Director/Chief Operating Officer, and Ken James, Executive Director and Head of R&D, will host a webcast for analysts on the day of the results, which will be made available within the investor centre section of the Company's website.

 

In light of growing concerns regarding COVID-19, the Company has decided to cancel its scheduled Investor Seminar, to be held on 26 March 2020. 

The Results webcast will now incorporate the Investor Seminar presentation which includes an extensive internal evaluation of the clinical data from the Phase 3 study ("FM57"), ongoing research and analysis of MED3000, as well as an update on regulatory discussions and insight into the erectile dysfunction market presented by Professor David Ralph, world leading expert in erectile dysfunction and male infertility and member of the Futura European KOL Advisory Panel.

For further information please contact:

Futura Medical plc

James Barder, Chief Executive

Angela Hildreth, Finance Director and COO

Email: [email protected] 

Tel: +44 (0) 1483 685 670

www.futuramedical.com

Nominated Adviser and Sole Broker:

Liberum

Bidhi Bhoma/ Euan Brown/ Kane Collings

Tel: +44 (0) 20 3100 2000

 

For media enquiries please contact:

 

Optimum Strategic Communications

Mary Clark/ Eva Haas/ Hollie Vile

Email: [email protected]

Tel: +44 (0) 203 950 9144


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NORDXLFFBXLBBBQ

Quick facts: Futura Medical PLC

Price: 19.25

Market: AIM
Market Cap: £47.28 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Futura Medical kicks off work on Phase III trial for erectile dysfunction gel

James Barder, chief executive of Futura Medical PLC (LON:FUM), tells Proactive they've begun preparatory work on the first Phase III efficacy trial for MED2002 - their topical gel for erectile dysfunction (ED). The study will recruit approximately 1,000 patients with mild, moderate and...

on 27/4/18